StockNews.AI
CVM
StockNews.AI
182 days

CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks

1. CEL-SCI's Multikine demonstrates pre-surgical tumor elimination in 3 weeks. 2. Q1 2025 results indicate significant potential for cancer treatment advancement.

2m saved
Insight
Article

FAQ

Why Bullish?

Positive trial results can boost CVM stock interest, similar to past biotech advancements.

How important is it?

This article highlights significant advancements in Multikine that could drive investor confidence in CVM.

Why Short Term?

Immediate investor sentiment may shift, leading to quick price adjustments.

Related Companies

CVMABUSKPTI
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reports fiscal Q1 2025 financial results: Multikine shows pre-surgical tumor elimination and regression in just 3 weeks.

Related News